Search results

TIGERTRIEVER™ 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic strokes

NEW ORLEANS & YOKNEAM, Israel--( BUSINESS WIRE )-- Rapid Medical™ , a leading developer of active endovascular devices, today announced late-breaking results from the DISTALS multicenter, randomized controlled trial showing that TIGERTRIEVER™ 13 achieved superior brain tissue reperfusion with an excellent safety profile when compared with medical management in medium vessel occlusion (MVO) stroke. The findings were presented in the main closing session at the 2026 International Stroke Conference (ISC) .

DALLAS, TEXAS- (September 21, 2023) – The NeVa CLEAR Study is a prospective, multicenter, open-label, single-arm, FDA-regulated IDE trial evaluating the safety and effectiveness of Vesalio’s technologically advanced NeVa device, renowned for its capacity to retrieve all clot types in large vessel occlusion (LVO) stroke. Primary results from the study were presented at the ESMINT annual meeting in Marseille, France (4-6 September 2023), where Vesalio also announced the fifth anniversary of NeVa’s international commercialization, making this milestone a dual celebration for the Vesalio team.

Phenox today announced the full European launch of the pRESET 5-40 and pRESET LUX 4-20 thrombectomy devices after receiving CE mark approval last year.